Can you put weight on with Wegovy — and why does it happen?

What STEP 1 found, and what it didn't guarantee

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight over 68 weeks. Those on semaglutide 2.4 mg lost an average of around 15% of body weight, a result that rightly generated significant clinical interest. The keyword there is average. The distribution around that mean is wide. Roughly one in seven participants on the active treatment lost under 5%, and a small proportion saw negligible change or a very modest gain. These outcomes weren't buried; they were reported. Weight loss medicines work through biological pathways that vary between individuals, metabolism, gut-hormone sensitivity, baseline insulin resistance and body composition all play a role. Wegovy is not a fixed formula applied to a fixed machine.

What the trial does not show is that putting on weight while taking Wegovy is common. True gain above starting weight during treatment is rare and usually traceable to a specific cause. The more frequent concern is a slower-than-expected response, or a plateau after initial loss. Those are different problems, and worth separating.

Reasons some people see a gain or no loss in the early weeks

The first four to eight weeks on Wegovy are a titration phase. Semaglutide starts at 0.25 mg and is stepped up by the prescriber over several months. At the lower doses, appetite suppression is mild, and some people unconsciously compensate, eating slightly more during the brief windows when nausea eases, for example. Fluid retention can also cause the scale to move upward briefly, masking any fat loss that is occurring. This early wobble is not the same as a medicine failing.

Beyond the titration period, certain factors genuinely impair the response. Corticosteroids, some antidepressants and a handful of antidiabetic medicines are known to promote weight gain independently of Wegovy's effect. Poor sleep drives ghrelin upward and suppresses leptin, both shifts push appetite in the wrong direction, partly counteracting the GLP-1 signal. Chronic stress has a similar effect through cortisol. How Wegovy affects body weight is shaped by far more than the injection alone, which is why prescribers ask about your full picture rather than just your BMI.

Worth noting: a few people report mild water retention around the time of their weekly injection, which can fluctuate on the scale by a kilogram or two. Daily weigh-ins amplify this noise. Weekly or fortnightly measurements at the same time of day are more informative.

Weight gain after stopping Wegovy, a separate but important question

The clearest data on weight regain comes from the STEP 4 extension study, and the pattern is consistent with what stopping Wegovy does to appetite: once semaglutide clears the body, hunger returns to pre-treatment levels. In STEP 4, participants who discontinued after 20 weeks regained roughly two-thirds of their lost weight within 48 weeks. The NHS describes weight management medicines as a long-term support tool rather than a short course, a point the NHS semaglutide medicines page makes plainly.

This matters for people weighing up whether to start, pause or continue treatment. A holiday, a busy patch at work, or even just an awkward Monday order, practical interruptions happen. But abrupt stops without a prescriber's input can accelerate regain. If your circumstances make sustained treatment difficult, that is precisely the kind of conversation to have with whoever is overseeing your care, before pausing rather than after. You can also read more about whether weight comes back after Wegovy and what the longer-term picture looks like.

When to raise this with a prescriber

If you are taking Wegovy at the maintenance dose and have gained weight over four or more consecutive weeks (not a single blip, but a consistent trend) that is worth flagging to the clinician managing your treatment. Possible explanations include a medicine interaction, an underlying condition affecting your response, or a technical issue with injection technique or storage. Putting on weight while on Wegovy is unusual enough that it warrants investigation rather than simply waiting it out.

Similarly, if you were previously responding well and have plateaued, NICE's guidance on semaglutide notes that continuing beyond six months is reviewed if less than 5% weight loss has been achieved at the maintenance dose, so the clinical framework already accounts for variable response. The cost of treatment over the long term is worth considering as part of this conversation; the Wegovy cost landscape in the UK has shifted significantly over the past year.

At nume, a named GPhC-registered prescriber reads every consultation and every repeat review personally. If something in your response pattern needs attention, the clinical team is the right first stop. Start your free consultation to discuss whether Wegovy is appropriate for your situation and what monitoring looks like in practice.